Indivior Pharmaceuticals, Inc.
addiction treatment and CNS pharmaceuticals
INDV · Nasdaq · United States
Share price · INDV
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when INDV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Aug 2026+6.1%
Nothing announced by INDV that day or the session before.
- 3 Aug 2026-6.6%
- 30 Apr 2026+7.7%
- 23 Feb 2026-2.8%
Nothing announced by INDV that day or the session before.
- 3 Nov 2025+6.2%
Share of unusual movement by asset
For each asset, the share of INDV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
buprenorphine extended-release(SUBLOCADE) | Approved | Mu-opioid receptor (partial agonist)Small molecule | Substance Use Disorder Opioid Use Disorder |
nalmefene nasal spray(OPVEE) | Approved | Opioid receptorSmall molecule | Substance Use Disorder Opioid Overdose Reversal |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (10)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $356M | $5.0M | $305M | —$97M operating cash flow | report ↗ |
View 9 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $343M | $12M | $222M | —$229M operating cash flow | report ↗ |
| 2026-Q1 | $317M | $16M | $175M | —-$9.0M operating cash flow | report ↗ |
| 2025-Q3 | $314M | $33M | $445M+ $0 short-term inv. | —-$39M operating cash flow | report ↗ |
| 2025-Q2 | $302M | $21M | $510M+ $0 short-term inv. | —$158M operating cash flow | report ↗ |
| 2025-Q1 | $266M | $22M | $372M+ $1.0M short-term inv. | —$75M operating cash flow | report ↗ |
| 2024-Q4 | — | — | $319M+ $1.0M short-term inv. | —-$17M operating cash flow | report ↗ |
| 2024-Q3 | $307M | $22M | $288M | —$2.0M operating cash flow | report ↗ |
| 2024-Q2 | $299M | $26M | $302M | $97M$88M operating cash flow | report ↗ |
| 2024-Q1 | $284M | $28M | $248M | —-$37M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.2B | $97M | $195M+ $0 short-term inv. | —-$27M operating cash flow | report ↗ |
For FY2025, the company reported revenue of $1,239M, up 4.3% YoY, with R&D spend of $97M, down 9.3% YoY. Cash and equivalents were $195M, and the company recorded GAAP net income of $210M.
The company reaffirmed its full-year 2026 guidance of net revenue of $1,125M to $1,195M, total SUBLOCADE net revenue of $905M to $945M, non-GAAP operating expenses of $430M to $450M, and adjusted EBITDA of $535M to $575M. Key disclosed events included the launch of a nationwide direct-to-consumer campaign, conclusion of the legacy DOJ matter with a $295M payment, completion of the redomiciliation to the U.S., entry into Phase II of the Indivior Action Agenda Accelerate, and authorization of a new $400M share repurchase program.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $1.2B | $107M | $319M+ $1.0M short-term inv. | —$36M operating cash flow | report ↗ |
| 2023-FY | $1.1B | $116M | $316M+ $94M short-term inv. | $32M-$300M operating cash flow | report ↗ |
| 2022-FY | $901M | $74M | $774M | $11M-$4.0M operating cash flow | report ↗ |
| 2021-FY | — | — | $1.1B | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 10 purchases ($312K), 3 sales ($2.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Rubin Jonathan · SVP, Chief Medical Officer | Other (see filing) | 21,529 | — | — | Form 4 |
| 2026-11-02 | Khattar Jack A. · director, Chief Executive Officer | Other (see filing) | 1,937,986 | — | — | Form 4 |
| 2026-11-02 | GEMAYEL GEORGES · director | Other (see filing) | 42,009 | — | — | Form 4 |
| 2026-11-02 | Sensenig Bethany · director | Other (see filing) (derivative) | 4,603 | — | — | Form 4 |
| 2026-11-02 | Bhatt Padmanabh P. · SVP of IP, CSO | Other (see filing) | 28,702 | — | — | Form 4 |
| 2026-11-02 | Barlow Carrolee · director | Other (see filing) | 41,652 | — | — | Form 4 |
| 2026-11-02 | DEC TIMOTHY C · SVP, Chief Financial Officer | Other (see filing) | 14,059 | — | — | Form 4 |
| 2026-11-02 | Horich William Todd · SVP, Chief Commercial Officer | Other (see filing) (derivative) | 20,021 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 287 reporting institutions held 127.5M shares ($3.8B, 108.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 18,542,220 | $565.2M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,891,819 | $240.5M |
| 3 | OAKTREE CAPITAL MANAGEMENT LP | 6,984,102 | $212.9M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5,586,576 | $170.3M |
| 5 | STATE STREET CORP | 4,903,993 | $149.5M |
| 6 | Two Seas Capital LP | 4,746,510 | $144.7M |
| 7 | MILLENNIUM MANAGEMENT LLC | 4,595,535 | $140.1M |
| 8 | FULLER & THALER ASSET MANAGEMENT, INC. | 4,529,583 | $138.1M |
| 9 | Madison Avenue Partners, LP | 4,315,162 | $131.5M |
| 10 | CITADEL ADVISORS LLC | 3,574,044 | $108.9M |
| 11 | MORGAN STANLEY | 3,505,817 | $106.9M |
| 12 | DEERFIELD MANAGEMENT COMPANY, L.P. | 3,097,790 | $94.4M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 2,925,688 | $89.2M |
| 14 | MANGROVE PARTNERS IM, LLC | 2,742,434 | $83.6M |
| 15 | GOLDMAN SACHS GROUP INC | 2,409,165 | $73.4M |